HiberGene

HiberGene develops, manufactures and markets molecular diagnostic tests for the direct detection of human infectious diseases, using LAMP technology.

[HiberGene @HiberGene]

#Meningococcal infection can exhibit enormous mortality rates, so early #diagnosis is crucial for successful treatment.

That’s why we developed our non-invasive direct swab, providing accurate results up to 72 times faster than culture methods: https://t.co/QIvVdK1ewU

[HiberGene @HiberGene]

When new-born babies are given strong #antibiotics to treat #GroupBStrep, it can sometime disrupt the development of their #ImmuneSystems.

But researchers at @CincyChildrens have discovered a promising form of protection: https://t.co/3QaTH0FkZr

[HiberGene @HiberGene]

#DidYouKnow that #GroupBStreptococcus (GBS) is carried by 20-30 % of pregnant women?

This puts babies at risk of infection, which is why we developed our HG GBS rapid, real-time #intrapartum test that aims to reduce mortality and morbidity: https://t.co/PBPmKF4gzE

[HiberGene @HiberGene]

July marked international #GroupBStrep awareness month!

With this fresh in our minds, we thought we'd share this @UHSFT article that outlines plans for a new #ClinicalTrial, testing a novel #vaccine against #GroupBStreptococcus infection: https://t.co/QtiepACpat

[HiberGene @HiberGene]

We are delighted to announce our latest PCR assay - PCR Adapt Covid-19/Flu Combo.
This is an RT-qPCR test for the direct detection and differentiation of #Covid19 and #Flu A & B, without sample extraction. #pcrtesting #moleculardiagnostics
https://t.co/Ol6D6VSIvf

[HiberGene @HiberGene]

We’ve recently seen another rise in #COVID19 cases, but we’re in a better position for #treatment and #testing.

If you're a #healthcare worker, look at our PCR Adapt for COVID-19! It's a high-throughput test, providing results in just 55-70 minutes: https://t.co/KJ0Stea9ck

[HiberGene @HiberGene]

We’re not short of #LessonsLearned from #COVID19.

But something essential to take forward with us, as we learn to live in this ‘new normal’, is #MultiPathogen diagnostics.

This @Telegraph article explains what this means for #healthcare systems: https://t.co/A3kvTUrmfl

[HiberGene @HiberGene]

If you’re new, here’s what we do…

We’re a leader in the design, development and manufacture of rapid analysis #MolecularDiagnostics, whether you work in #PointOfCare or in a #Laboratory setting

Take a look around our website to learn more: https://t.co/HjtrFtKaak

[HiberGene @HiberGene]

#ClinicalDiagnosis of #Sepsis has previously relied on identifying symptoms appearing at the more damaging, later stages of the condition.

But, this @dailynexus article outlines how #MolecularDiagnostic testing could recognise the early stages: https://t.co/OXFbnCOZMO

[HiberGene @HiberGene]

We provide superior testing solutions covering many disease areas, including respiratory, infectious and women��s health.

They are all designed to improve patient management, as well as save money and time.

Take a look at our entire range: https://t.co/udMJrAGuyz

[HiberGene @HiberGene]

@7Noel22 [email protected]

[HiberGene @HiberGene]

Are you on the search for a #MolecularDiagnostics company with deep technical knowledge about a variety of testing solutions, and how they can be matched to benefit end-user requirements?

Look no further!

Get in touch today: https://t.co/Mz7J08a1wr

[HiberGene @HiberGene]

The BA.2.75 variant “Centaurus” was first detected in India in May. Cases in the UK have since risen steeply – and apparently faster than those of the extremely transmissible BA.5 variant. #covid19test https://t.co/IBHCfnjsQb

[HiberGene @HiberGene]

Using #DiagnosticTesting to correctly identify conditions can prevent inappropriate #drug use, helping to combat #AntibioticResistance.

The @FinancialTimes recently outlined how improved diagnostic tools are essential to this: https://t.co/aXIpwHP1QN

[HiberGene @HiberGene]

The latest #variants are masters at evading immunity – previous infection & vaccines unlikely to provide much protection. #https://www.theguardian.com/world/2022/jul/05/new-covid-variants-ba4-ba5-most-contagious-australia-third-omicron-wave-coronavirus-subvariants-ba-4-5

[HiberGene @HiberGene]

Our #Molecular #DiagnosticTesting solutions provide cost-effective and rapid delivery of results at #PointOfCare or in a #laboratory setting.

To do this, we offer compact instruments that can analyse up to 48 samples simultaneously.

Learn more: https://t.co/DF0Rf0xGGG

[HiberGene @HiberGene]

We’re pleased to say – after huge success in Ireland – we’ll now be directly supplying our #InfectiousDisease testing solutions to #healthcare customers across the UK!

Check out this @Labmate_online article to see the full announcement: https://t.co/9spunS08f6

[HiberGene @HiberGene]

We are excited to announce the launch of a new dedicated team, focusing on supplying products directly to the UK!

This growth means that we will be able to increase our geographical reach, as well as place us in an enhanced position to better serve all our UK-based customers.

[HiberGene @HiberGene]

Researchers are emphasising the need for a clinical trial with the goal of identifying whether screening pregnant women for #GroupBStrep infection – like the USA – reduces baby mortality or morbidity.

Testing for #GBS is vital for saving lives
https://t.co/tthQIQTa0q

[HiberGene @HiberGene]

July is #GBSawarenessmonth!
HG #GroupBStreptococcus allows for #antepartum GBS screening, intrapartum testing and testing at-risk or symptomatic newborns for optimal treatment of GBS.
https://t.co/rDvIxB0YGk

#moleculardiagnostics #intrapartumtesting #groupbstrep #gbsaware